Skip to main content
Sign In

About the Program

                     Thomas L. Petty Aspen Lung Conference
                                  59th Annual Meeting
           “Lung Transplantation: Opportunities for Repair and Regeneration”
                            Martin R. Zamora, M.D., Chair
             Tereza Martinu, M.D. and Mark R. Nicolls, M.D., Co-Chairs
                                    June 8-11, 2016
                             The Gant Conference Center
                                    Aspen, Colorado
The life cycle of a lung transplant spans donation, explantation, preservation, implantation and finally accommodation. Through each of these stages innate and adaptive responses involving inflammation and fibrosis can harm the life-saving graft. Emerging insights into these events create the potential for new interventions that promote organ health and patient survival. With an emphasis on integration of basic, translational and clinical approaches, the 59th Annual Aspen Lung Conference will focus on the central question of each of these stages: how can knowledge of the mechanisms underlying allograft injury, airway inflammation and remodeling be translated into effective approaches to improve long-term allograft survival? To address this central question, the program will be organized into a series of thematic sessions focusing on (i) new concepts in lung allograft preservation and reconditioning utilizing ex-vivo lung perfusion, (ii) adaptive immunity including new arenas in T cell and B cell biology, (iii) host response/innate immune mechanisms, (iv) airway/allograft remodeling and (v) strategic approaches to translating scientific advances into impactful therapy including molecular phenotyping, novel immunosuppression and development of novel diagnostic and monitoring techniques. These diverse themes will be reconciled in a concluding Conference Summary presented by Michael A. Matthay, M.D., Professor of Medicine and Anesthesia, University of California, San Francisco.   Our overall objective is to assemble thought leaders in transplantation to educate the next generation of scientists and define the next big steps to be taken in the field.
Abstract deadline is February 14, 2016.  For more information, contact: Martin R. Zamora, M.D., c/o Jeanne Cleary, Thomas L. Petty Aspen Lung Conference, PO Box 1622, Parker, CO 80134   Phone:  (303) 358-2797.  Fax:  (720) 851-1034. 

1.        To provide an international forum for leading clinicians and researchers to exchange ideas regarding fundamental concepts underlying innate responses during all phases of lung transplantation including lung inflammation during preservation injury and implantation, airway immunology, genetics/genomics, pathology, molecular biology and novel monitoring and diagnostic methods. 
2.       To showcase recent advances in lung transplantation and to explore ongoing challenges in allograft health and survival. The goal is to stimulate interactions and facilitate concept integration between the often siloed scientific fields of clinical lung transplantation, immunology and pathology and ultimately identify and integrate emerging, shared interests such as innate immune dysregulation, fibrosis and regeneration.
3.       To move forward the concept of molecular and clinical phenotyping of lung transplant complications including  ischemia reperfusion injury or primary graft dysfunction, acute rejection and chronic lung allograft dysfunction to improve the efficiency and success of translating scientific advances into direct patient benefit as well as strategies to better prioritize scientific questions based on clinical needs.
4.       To challenge and thereby stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the field of transplant pathobiology.
At the conclusion of this conference attendees will be able to:
1)     Discuss State-of-the-Art concepts regarding the pathophysiological continuum between lung inflammation, immunology and the heterogeneity of lung allograft dysfunction phenotypes.
2)     Appreciate the complex interactions between endothelial and epithelial cells, inflammatory cells and matrix which modulate the processes of lung innate and adaptive immunity in lung allograft rejection.
3)     To translate basic concepts and to understand challenges in current clinical trial design, and identify approaches to maximize the efficacy of translation of basic science advances in lung injury and repair.
4)     Apply principles of lung transplant injury and regeneration to other inflammatory pulmonary conditions which might similarly benefit by these lines of inquiry.  
Intended Audience:  Local/Regional/National/International
Physicians/clinicians (adult and pediatric)/Research Physician-Scientists-Transplant, Pulmonary Sciences, Critical Care and Sleep Medicine/Primary Care Physicians/General Medicine Physicians/Public Health.

AMEricans with Disability Act statement 
Please indicate if you have any need for auxiliary aids or special assistance services